胃癌：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計西班牙胃癌市場將從2025年的2.2億美元成長到2035年的5.8億美元。
• 該成長得益於生物標記檢測的擴展和靶向癌症療法的引進。
• 研發的治療方法，包括與抗體藥物偶聯物（ADC）和免疫療法的聯合治療，有望加速市場擴張。

胃癌概述

胃癌是全球第五大常見癌症，也是第五大癌症死亡原因，且男性發生率顯著高於女性。其病因複雜，受環境和感染等危險因子的強烈影響。幽門螺旋桿菌感染是遠端（非賁門）胃癌的主要原因，其他促發因素包括高鹽飲食、接觸N-亞硝基化合物、食用燻製食品和吸菸。同時，高BMI、胃食道逆流症（GERD）和吸菸與近端胃和胃食道交界處（GEJ）腺癌的發生率顯著相關。在分子層面上，纖維母細胞生長因子（FGF）透過與其受體（FGFR）結合並誘導下游訊號傳遞發揮關鍵作用。特別是，FGFR2b異構體作為一種新的預後和預測生物標記正受到廣泛關注。在高達38%的晚期胃癌中觀察到不同程度的FGFR2b蛋白過度表達，其中約16%的病例存在臨床可干預的高水準過表達，尤其是在瀰漫型和硬癌中。 FGFR2基因擴增（可獨立於蛋白質過度表現發生）在約5-10%的病例中觀察到。所有這些突變均與腫瘤深部浸潤、侵襲性生長和預後不良相關，凸顯了新型標靶治療（例如標靶FGFR2b的單株抗體bemarituzumab）的重要性。

主要亮點

• 根據預測，德國胃癌的生存調整病例數將從2025年的120,844 例增加到2035年的129,241 例。
• 由於胃癌通常在晚期才被診斷出來，因此它仍然是一個重大的臨床負擔。
• HER2標靶治療方法和免疫療法正日益影響治療模式。
• 在治療進行性和轉移性疾病方面，仍存在大量未滿足的需求。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

主要企業

• AstraZeneca
• Bristol-Myers Squibb
• Bold Therapeutics, Inc.
• RemeGen Co., Ltd.
• Ono Pharmaceutical Co., Ltd.
• Idience Co., Ltd.
• MacroGenics
• ImmVirx Pty Ltd
• Chimeric Therapeutics
• Qurgen Inc.
• Amgen
• Daiichi Sankyo
• AskGene Pharma, Inc.
• ALX Oncology Inc.
• Shanghai Henlius Biotech
• Merck Sharp &Dohme LLC
• Teclison Ltd.
• Iksuda Therapeutics Ltd.
• Cue Biopharma
• Genome &Company
• Hoffmann-La Roche
• Qurient Co., Ltd.
• MedPacto, Inc.
• ArriVent BioPharma, Inc.
• MOMA Therapeutics
• Aprea Therapeutics
• Genentech, Inc.
• Perspective Therapeutics
• HiFiBiO Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Monopar Therapeutics
• Sanofi
• Celldex Therapeutics
• SillaJen, Inc.
• Jazz Pharmaceuticals
• Incyte Corporation
• TransThera Sciences（Nanjing）, Inc.
• Nurix Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Sutro Biopharma, Inc.
• Inhibrx Biosciences, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• Apollomics Inc.

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法 - 概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章 未滿足的需求與TPP分析

• 主要未滿足的需求及其未來透過新興治療方法實現的可能性
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Gastric Cancer Market Outlook

Thelansis's "Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gastric Cancer Overview

Gastric cancer is the fifth most commonly diagnosed cancer worldwide and the fifth leading cause of cancer-related death, with a notably higher prevalence in men. Its pathogenesis is complex and heavily influenced by environmental and infectious risk factors; while Helicobacter pylori infection is the primary driver of distal (non-cardia) gastric cancers, other contributors include high-salt diets, N-nitroso compound exposure, smoked foods, and smoking. Conversely, increased BMI, gastroesophageal reflux disease (GERD), and smoking are strongly associated with the rising incidence of adenocarcinomas of the proximal stomach and gastroesophageal junction (GEJ). Molecularly, fibroblast growth factors (FGFs) play a pivotal role by binding to their receptors (FGFRs), triggering downstream oncogenic signaling cascades. Specifically, the FGFR2b isoform is an emerging prognostic and predictive biomarker. FGFR2b protein overexpression occurs to some degree in up to 38% of advanced gastric cancers-with clinically actionable, high-level overexpression present in approximately 16% of cases-particularly in diffuse-type and scirrhous subtypes. FGFR2 gene amplification, which can occur independently of protein overexpression, is seen in about 5-10% of cases. Both alterations correlate with deeper invasion, infiltrative growth, and a poor prognosis, underscoring the critical importance of emerging targeted treatments like the FGFR2b-directed monoclonal antibody bemarituzumab.

Key Highlights

• In Germany, survival-adjusted prevalent Gastric Cancer cases are projected to increase from 120,844 in 2025 to 129,241 by 2035.
• Gastric cancer continues to impose significant clinical burden due to late-stage diagnosis.
• HER2-targeted therapies and immunotherapies are increasingly influencing treatment paradigms.
• Unmet need remains high in advanced and metastatic disease management.

Market Overview

• The Spain Gastric Cancer market is projected to grow from USD 220 million in 2025 to USD 580 million by 2035.
• Growth is supported by expanding biomarker testing and adoption of targeted oncology therapies.
• Pipeline therapies including ADCs and immunotherapy combinations are expected to accelerate market expansion.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• AstraZeneca
• Bristol-Myers Squibb
• Bold Therapeutics, Inc.
• RemeGen Co., Ltd.
• Ono Pharmaceutical Co., Ltd.
• Idience Co., Ltd.
• MacroGenics
• ImmVirx Pty Ltd
• Chimeric Therapeutics
• Qurgen Inc.
• Amgen
• Daiichi Sankyo
• AskGene Pharma, Inc.
• ALX Oncology Inc.
• Shanghai Henlius Biotech
• Merck Sharp & Dohme LLC
• Teclison Ltd.
• Iksuda Therapeutics Ltd.
• Cue Biopharma
• Genome & Company
• Hoffmann-La Roche
• Qurient Co., Ltd.
• MedPacto, Inc.
• ArriVent BioPharma, Inc.
• MOMA Therapeutics
• Aprea Therapeutics
• Genentech, Inc.
• Perspective Therapeutics
• HiFiBiO Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Monopar Therapeutics
• Sanofi
• Celldex Therapeutics
• SillaJen, Inc.
• Jazz Pharmaceuticals
• Incyte Corporation
• TransThera Sciences (Nanjing), Inc.
• Nurix Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Sutro Biopharma, Inc.
• Inhibrx Biosciences, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• Apollomics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)